Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accredited, affiliated, Amgen, atezolzumab, back, Biopharma, bladder, broad, cervical, Circuit, deadline, died, evidencing, fractional, fulfilling, hearing, Hunt, interstitial, Israel, KOL, language, Leaf, lieu, pertaining, pose, preexisting, ratio, rental, reset, robust, Ron, RRMM, RSU, Sanofi, straight, Unitary, UPC
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view